Effect of SC 38249, a Novel Substituted Imidazole, on Platelet Aggregation In Vitro and In Vivo

N Lad; A C Honey; D O Lunt; R F G Booth; J Westwick; P W Manley; D P Tuffin

doi:10.1055/s-0038-1642747

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1988; 59(02): 164-170
DOI: 10.1055/s-0038-1642747

Original Articles

Schattauer GmbH Stuttgart

Effect of SC 38249, a Novel Substituted Imidazole, on Platelet Aggregation In Vitro and In Vivo

Authors

N Lad

Searle Research & Development, High Wycombe, Buckinghamshire, UK
A C Honey

Searle Research & Development, High Wycombe, Buckinghamshire, UK
D O Lunt

Searle Research & Development, High Wycombe, Buckinghamshire, UK
R F G Booth

Searle Research & Development, High Wycombe, Buckinghamshire, UK
J Westwick

¹Department of Pharmacology, Royal College of Surgeons of England, Lincoln's Inn Fields, London WC2A 3PN, UK
P W Manley

Searle Research & Development, High Wycombe, Buckinghamshire, UK
D P Tuffin

Searle Research & Development, High Wycombe, Buckinghamshire, UK

Abstract

PDF Download

Summary

SC 38249 ((RS)-l-(2,3-bis-[(4-methoxyphenyl)methoxy] propyl)-lH-imidazole) caused dose-related inhibition of collagen- induced thromboxane A₂ formation in human platelet rich plasma (IC₅₀: 9.9 ± 1.0 μM) accompanied by a dose-dependent increase in plasma PGE₂. Broad inhibitory activity was evident against human platelet aggregatory and secretory responses in vitro.IC₅₀ values of 11.9 ± 1.9 μM (0.64 mM arachidonic acid), 18.3 ± 3.8 μM (0.5 μg ml−^-1collagen) and 37.6 ± 6.1 μM (25 nM Paf-acether) were obtained against maximum increase in PRP light transmission achieved by each agonist. Although less potent, SC 38249 retained significant inhibitory activity against PRP responses induced by a higher (3.0 μg ml−^-1) concentration of collagen (IC₅₀: 272.5 ± 24.6 μM), and against Paf-acether-induced responses in PRP pre-treated with 10 μM indomethacin (I.C.₅₀: 192.0 ± 16.1 μM).Experimental animal studies confirmed the in vitroanti-aggregatory efficacy of SC 38249, since significant inhibitory activity was observed against Paf-acether and ADP-induced responses in dog PRP ex vivo,anti-Forssman antibody-induced thrombocytopoenia in anaesthetized guinea pigs, and collagen-induced intravascular aggregation in anaesthetized rabbits. Thus, SC 38249 is a novel thromboxane synthase inhibitor which possesses interesting anti-aggregatory properties which cannot wholly be attributed to prevention of platelet thromboxane A₂ formation.

Keywords

SC 38249 - Thromboxane synthase inhibitor - Anti-aggregatory properties

PDF (457 kb)

References

References
1 Hamberg M, Svensson J, Samuellson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U.S. A. 1975; 72: 2994-2998
2 Bhagwat SS, Hamann PR, Still WC. Synthesis of thromboxane A₂ . J Am Chem Soc 1985; 107: 6372-6376
3 Miyamoto T, Taniguchi K, Tanouchi T, Hirata F. Selective inhibitor of thromboxane synthetase: pyridine and its derivatives. Adv Prost Thrombox Res 1980; 6: 443
4 Randall MJ, Parry MJ, Hawkeswood E, Cross PE, Dickinson RP. UK 37248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity. Thromb Res 1981; 23: 145-162
5 Ambler J, Butler KD, Ku EC, Maguire ED, Smith JR, Wallis RB. CGS 12970 A novel long-acting thromboxane synthetase inhibitor. Br J Pharmac 1985; 86: 497-504
6 Kato K, Ohkawa S, Terao S, Terashita Z, Nishikawa K. Thromboxane synthetase inhibitors (TXSI). Design, synthesis and evaluation of a novel series of opyridyl alkenoic acids. J Med Chem 1985; 28: 287-294
7 Olson RW, Cohen DS, Ku EC, Kimble EF, Renfroe HB, Smith EF. CGS 15435A, a thromboxane synthetase inhibitor with an extended duration of action: a comparison with dazoxiben. Eur J Pharmacol 1987; 133: 265-273
8 Hall ER, Chen Y-C, Ho T, Wu KK. The reduction of platelet thrombi on damaged vessel wall by a thromboxane synthetase inhibitor in rabbits. Thromb Res 1982; 27: 501-511
9 Shea MJ, Driscoll EM, Romson JL, Pitt B, Lucchesi BR. Effect of OKY 1581, a thromboxane synthetase inhibitor, on coronary thrombosis in the conscious dog. Eur J Pharmac 1984; 105: 285-291
10 Tomoda H. Development of an experimental model of acute myocardial infarction and the effects of a thromboxane synthetase inhibitor (OKY-046). Am Heart J 1986; 112: 696-704
11 Katayama Y, Shimizu J, Memezawa H, Minamisawa H, Suzuki S, Sugimoto S, Terashi A. Protective effect of thromboxane A₂synthetase inhibitor (trapidil) on acutely-induced cerebral ischaemia. Brain Nerve 1986; 38: 925-931
12 Butler KD, Butler PA, Shand RA, Ambler J, Wallis RB. Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970(3-methyl-2-(3-pyridyl)-l-indoleoctanoic acid) and dazoxiben. Thromb Res 1987; 45: 751-761
13 Manley PW, Allanson NM, Booth RF G, Buckle PE, Kuzniar EJ, Lad N, Lai SM F, Lunt DO, Tuffin DP. Structure-activity relationships in an imidazole-based series of thromboxane synthase inhibitors. J Med Chem 1987; 30: 1588-1595
14 Lad N, Lunt DO, Tuffin DP. The effect of thromboxane A₂ synthesis inhibitors on platelet aggregation in whole blood. Thromb Res 1987; 46: 555-566
15 Mehta P, Mehta J, Ostrowski N, Aguila E. Potentiation of platelet aggregation by chronolume. Thromb Res 1983; 32: 509-512
16 Thompson NT, Scrutton MC. Inhibition by luciferin-luciferase reagents of aggregatory responses to excitatory agonists in washed platelet suspensions. Thromb Res 1985; 38: 109-119
17 Banerjee AK, Tuffin DP, Walker JL. Pharmacological effects of (±)-ll-deoxy, 16-phenoxy prostaglandin Ej derivatives in the cardiovascular system. Br J Pharmac 1985; 84: 71-80
18 Honey AC, Lad N, Tuffin DP. Effect of indomethacin and dazoxiben on intravascular platelet aggregation in the anaesthetized rabbit. Thromb Haemostas 1986; 56: 80-85
19 Smith GM, Freuler F. The measurement of intravascular aggregation by continuous platelet counting. Bibl Anat 1973; 12: 257-265
20 Steinhauer HB, Lubrich I, Gunter B, Schollmeyer P. Response of human platelets to inhibition of thromboxane synthesis. Clin Haemorheol 1983; 3: 1-12
21 Ku EC, McPherson SE, Signor C, Chertock H, Cash WD. Characterization of imidazo[l,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivobiochemical models. Biochem Biophys Res Comm 1983; 112: 899-906
22 Gorman RR, Johnson RA, Spilman CH, Aiken JW. Inhibition of platelet thromboxane A₂ synthase activity by sodium 5-(3’-pyridinyl- methyl)benzofuran-2-carboxylate. Prostaglandins 1983; 26: 325-342
23 Hiraku S, Wakitani K, Katsube N, Kawasaki A, Tsuboshima M, Naito J, Ujiie A, Komatsu H, Iizuka K. Pharmacological studies on OKY 1581 a selective thromboxane synthetase inhibitor. Adv Prost Throm- box Res 1983; 11: 241-244
24 Heptinstall S, Bevan J, Cockbill SR, Hanley SP, Parry MJ. Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb Res 1980; 20: 219-230
25 Bertele V, Falanga A, Tomasiak M, Chiabrando C, Cerletti C, De Gaetano G. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclo-oxygenase products. Blood 1984; 63: 1460-1466
26 Dale J, Thaulow E, Myhre E, Parry J. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism. Thromb Haemostas. 1983 50.
27 Ito T, Ogawa K, Sakai K, Watanabe J, Satake T, Kayama N, Hiraku S, Naito J. Effects of a selective inhibitor of thromboxane synthetase (OKY 1581) in humans. Adv Prost Thrombox Res 1983; 11: 245-251
28 Hornby EJ, Skidmore IF. Evidence that prostaglandin endoperoxides can induce platelet aggregation in the absence of thromboxane A₂ production. Biochem Pharmacol 1982; 31: 1158-1160
29 Rajtar G, Cerletti C, Castagnoli MN, Bertele V, De Gaetano G. Prostaglandins and human platelet aggregation: implications for the anti-aggregating activity of thromboxane synthetase inhibitors. Biochem Pharmacol 1985; 34: 307-310
30 Grimm LJ, Knapp DR, Senator D, Halushka PV. Inhibition of platelet thromboxane synthesis by 7-(l-imidazoyl)heptanoic acid, dissociation from inhibition of aggregation. Thromb Res 1981; 24: 307-317
31 Gorman RR. Biology and biochemistry of thromboxane synthetase inhibitors. Adv Prost Thrombox Res 1983; 11: 235-240
32 Marcus AJ, Safier LB, Ullman HL, Wong KT H, Brockman MJ, Weksler BB, Kaplan KL. Effects of acetyl glyceryl ether phosphoryl- choline on human platelet function in vitro. . Blood 1981; 58: 1027-1031
33 McManus LM, Hanahan DJ, Pinckard RN. Human platelet stimulation by acetyl glyceryl ether phosphorylcholine. J Clin Invest 1981; 67: 903-906
34 Chignard M, Coeffier E, Benveniste J. Role of Paf-acether and related ether-lipid metabolism in platelets. Adv Exp Med Biol 1985; 192: 309-326
35 Tuffin DP, Davey P, Dyer RL, Lunt DO, Wade PJ. Specific binding of [³H]-1 -O-octadecyl-Paf-acether to washed human platelets. Adv Exp Med Biol 1985; 192: 83-96
36 Darlow G. The effect of Forssman antibody on the circulation and respiration of the guinea pig. J Physiol 1965; 181: 350-364
37 Darlow G, Gough GF, Tanalp R. The involvement of the complement system in the pressor response to the injection of Forssman antibody in the guinea pig. J Physiol 1970; 206: 481-493
38 Newman S, Glovsky MM, Ghekiere MS, Alenty A. Quantitative requirements for C3 to induce Forssman systemic shock and cutaneous haemorrhagic vasculitis in guinea pigs. J All Clin Immunol 1977; 59: 327-333
39 Nagai H, Kurimoto Y, Koda A. Immunopharmacological approach to Forssman shock. Microbiol Immunol 1980; 24: 649-655
40 Pelczarska AB, Roszkowski AP. Inhibitors of Forssman guinea pig anaphylaxis. J Pharmacol Exp Ther 1973; 185: 116-126